Open-label, dose escalation phase 1 clinical trial of AlphaMedixTM for targeted alpha emitter therapy in adult patients with differentiated neuroendocrine tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2018
At a glance
- Drugs 212-Pb-AR-RMX (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; First in man
- 10 Jan 2018 According to a RadioMedix media release, patients will be enrolled at Excel Diagnostic and Nuclear Oncology Center (Houston, TX).
- 10 Jan 2018 Status changed from planning to recruiting, according to a RadioMedix media release.
- 03 Jul 2017 New trial record